摘要
目的:本研究旨在观察TSGF(肿瘤特异性生长因子)、CEA(癌胚抗原)在非小细胞肺癌(NSCLC)后程放疗同步化疗中的变化,评价以上肿瘤标志物的临床价值。方法:40例NSCLC患者均进行后程照射同步两周期化疗,分别于治疗前以及治疗完成后4周进行TSGF以及多肿瘤标志物蛋白芯片检测。结果:TSGF、CEA在治疗开始时的阳性率分别为62%、57%,治疗后各观测指标均显著性下降(P<0.05),尤其对于达CR的患者。对于治疗有效的患者,CEA阴性患者的近期生存期显著长于阳性患者。结论:NSCLC患者后程放疗同步TP方案化疗中,对于治疗有效患者TSGF、CEA的下降与影像学资料具有一致性;并且CEA可以作为预后指标。
Objective: Our research is to observe the change of TSGF, CEA in the late-course radiotherapy combined with chemotherapy in non-small-cell lung cancer, and to evaluate the clinical significance of the above tumor makers. Methods: Thirty-eight NSCLC patients were treated by late-course radiotherapy combined with two cycle chemotherapy, tested TSGF and multi-tumor maker protein chip at the beginning and weeks after therapy. Results: The positive rate of TSGF, CEA is 62%, 57% in the observed objectives at the therapy beginning. It indicates significant reducing change of TSGF and CEA after therapy compared with the indexes at the therapy beginning ( P 〈 0.05 ), especially to the patients that reach CR and PR curative effect. To the CR and PR patients that express negative CEA indicate long recent survival than positive patients ( P 〈 0. 05 ). Conclusion: To the lung cancer patients treated by late-course radiotherapy combined with TP chemotherapy who reach CR curative effect, the decreasing of TSGF keep consistence to the emerge change. CEA can be seemed as the prognosis indexes.
出处
《中国医药导刊》
2007年第4期346-348,共3页
Chinese Journal of Medicinal Guide